Mr. Martin Felsenthal serves as Partner at Health Velocity Capital. He also serves as a Board Member at WELL Health. He has worked exclusively with innovative, disruptive, and rapidly growing healthcare software and services companies for more than 20 years. He was previously a partner at two leading venture and growth capital firms focused on this sector -- Salix Ventures and HLM Venture Partners - and also worked with Madison Dearborn Partners earlier in his career. He has led investments in and/or served on the Boards of Directors of companies such as TelaDoc (NYSE: TDOC); Change Healthcare (acquired by Emdeon); Aperio (acquired by Leica Biosystems); Titan Health (acquired by United Surgical Partners); US Renal Care (acquired by Leonard Green); Payerpath (acquired by Misys/Allscripts); Vantage Oncology (acquired by McKesson); NovoLogix (acquired by CVS Health); VeriCare (acquired by MedOptions); OnShift; and ClearData Networks. Marty received his AB from Princeton University and his MBA from the Stanford University Graduate School of Business.